![]() ![]() Moving forward we believe we have sufficient capital to execute our near-term strategy and deliver long-term value for shareholders.” “We remain focused on maximizing the opportunity for GOCOVRI to benefit Parkinson’s disease patients, which includes our recently filed sNDA for a label revision to include OFF episodes. There remains a significant unmet need for this population and we are committed to completing the open-label study and publishing our data to benefit the MS community,” said Neil F. ![]() “As a patient focused company this was a difficult decision, and I want to thank the patients, healthcare professionals, and employees who contributed to this development program. Based on these findings, Adamas reconfirms it will not initiate further Phase 3 development in MSW. ![]() Food and Drug Administration (FDA) to fully understand a potential path to submission confirmed the need for an additional pivotal Phase 3 confirmatory study. Additional patient, physician, and payer research based on the revised profile projected a limited commercial opportunity. ( ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the completion of its evaluation of ADS-5102 in multiple sclerosis patients with walking impairment (MSW).Ī comprehensive analysis of the INROADS Phase 3 data validated the top line results announced in December 2019 and informed a revised target product profile reflecting the scale of clinical benefit observed in the study. EMERYVILLE, Calif., J(GLOBE NEWSWIRE) - Adamas Pharmaceuticals, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |